FDA
-
-
-
-
-
-
-
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
-
-
-
-
-
-
-
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
-
-
-
-
-
-
-
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
-
-
-
-
-
-
-
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
-
-
-
-
-
-
-
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
-
328,151 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

